Following an uncharacteristically quiet August, the Chicago tech scene was revived last month following several successful venture funding raises. Several companies secured fresh capital to advance their solutions in spaces like biotechnology, AI and more.

Top Chicago Tech Funding Rounds, September 2023
Evozyne
Kin Insurance
Vivante Health
Site Technologies
Teregonia

#4. (tied) $10 million, September 20
Teragonia wants to help private market investors and operators boost their productivity and investment returns. The platform launched with more than $10 million in seed funding. The company’s managed services platform provides digital capabilities to financial sponsors, using data to help them formulate and execute their investment theses.

SITE Technologies
#4. (tied) $10 million, September 12
SITE Technologies provides companies with an AI-enabled platform for asset management and data analytics. It recently secured a round of Series A funding led by Prologis Ventures that will allow it to invest in furthering its mission to empower the real estate industry with real-time data collection and AI property condition analysis.

Vivante Health
#3. $31 million, September 20
Operating a digital care platform for digestive health, Vivante will make upgrades to its tech to help predict the onset and progression of gastrointestinal conditions, as well as expand its commercial and client support teams. The company secured a round of Series B funding led by Mercato Partners that brings its total funding to $47 million.

Kin Insurance
#2. $33 million, September 13
QED Investors led the latest round of funding for Kin, an insurance tech company offering homeowners a platform for customized coverage and claim services. The company has raised a total of $265 million to date. Its most recent round strengthens its liquidity and allows it to fuel further growth.

Evozyne
#1. $81 million, September 27
Biotech company Evozyne offers a generative AI-powered drug discovery platform. Backed by a sizable Series B investment from Fidelity Management & Research Company, OrbiMed and others, Evozyne plans to fund its platform and further product development.

Originally reported here.